Attention Houston female founders — there are two new accelerator programs to have on your radars. Photo via Getty Images

A couple of Houston startup development organizations have recently announced programing and opportunities for female founders looking to advance their businesses.

Impact Hub Houston has announced that it has partnered up with Frost Bank to sponsor eight female founders to participate in Impact Hub's new Accelerate Membership Program. Applications are now open online and once the inaugural cohort is selected, they will receive the program for three months at no cost.

"At Impact Hub we believe the time to act is now. It's why we are excited to launch our new Accelerate Membership," says Maria Trindade, global network development director at Impact Hub Global, in a news release. "Its unique approach combines all the benefits of an enterprise support program with the flexibility that entrepreneurs need; plus its tailored nature makes this intervention highly accessible for entrepreneurs from diverse backgrounds who may not be able to dedicate full-time to their business idea."

Impact Hub Houston has also teamed up with MassChallenge for their own initiative supporting female founders in the Houston-Galveston region in partnership with Houston-based Workforce Solutions. The three organizations are collaborating to launch launch a bootcamp to support female founders in the greater Houston region.

"There is unprecedented growth in startup creation as a result of the pandemic and founders from all corners of the world are connecting in this virtual environment to build and scale amazing ideas," says Jon Nordby, managing director of MassChallenge Texas, in a news release. "With these new collaborations, we are also witnessing a massive gap in access to startup development resources. Our partnership with Workforce Solutions and Impact Hub Houston will help female founders build on their existing knowledge to become life-long innovators."

Applications for the bootcamp opened April 1 and will close at 5 pm on April 7 and are available online in both English and Spanish. The industry agnostic program will leverage MassChallenge's acceleration model and Impact Hub Houston's inclusive incubation expertise to accelerate female founders by connecting them with the resources they need to launch and scale high-impact businesses, according to the release.

"As a female founder myself, I'm incredibly excited about this opportunity to support and uplift more women entrepreneurs and women-led businesses in our region," says Grace Rodriguez, CEO and executive director of Impact Hub Houston, in the release. "By now, it's no secret that women, and especially women of color, are under-invested in; and this is our chance to change that by helping more women strengthen their businesses and prepare to seek funding."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”